Company profile

Addpharma

Korean pharma

Privately held: no public share price · South Korea

Assets

(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
AD-209
Phase 3
Angiotensin II type 1 receptor / L-type calcium channel (dual)Small molecule
Hypertension
AD-236A
Phase 1
Undisclosed / early pipeline
Atherosclerotic Cardiovascular Disease
AD-236A + AD-236B
Phase 1
Undisclosed / early pipeline
Atherosclerotic Cardiovascular Disease
AD-236B
Phase 1
Undisclosed / early pipeline
Atherosclerotic Cardiovascular Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.